XKEMQ.PK.

[GatewayStocks]

Closed with a bullish hammer over the 200 DMA, right at the top B. Band. Todays low was higher than yesterdays and volume is still strong for the OS size. Accumulation is heavy, it cant remain at these levels for long, has to go up or down soon. The sentiment, momentum and bull market conditions are strong enough to push it higher. It wants to run.

Also, the SAR jumped up today right under the hammer. Tomorrow should be a strong day if it gets the follow through.

Re-post from another chart board....GLTA

[GatewayStocks]

XKEM line chart. Clear picture of the stock bouncing off the 200 DMA. Same thing it did the last time it broke the 200 DMA and exploded!

I definately believe we are seeing the same thing here and it could happen in days...

[GatewayStocks]

Guru Alerts XKEM for Thursday, March 2, 2006

Thursday , March 02, 2006 07:52 ET

Dallas, Texas, Mar 02, 2006 (M2 PRESSWIRE via COMTEX) -- Stock Guru Alerts for Thursday Xechem International, Inc. (OTCBB:XKEM)

Xechem International, Inc. (OTCBB:XKEM) traded as much as 7.69% over open on Wednesday.

Xechem International, Inc. is a development stage biopharmaceutical company focusing on anticancer, antiviral (including AIDS), antifungal, Sickle Cell Disease (SCD), antimalarial and antibacterial products from natural sources, including microbial and marine organisms. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its focus is on the development of phyto-pharmaceuticals and other proprietary technologies, including those used in the treatment of orphan diseases. Its primary attention and resources are currently being directed toward the development and commercial launch of its Sickle Cell drug, NICOSAN(TM)/HEMOXIN(TM), which has shown efficacy in the treatment of SCD.

[GatewayStocks]

XKEM: Obasanjo to launch locally produced sickle cell drug
3-3-06

President Olusegun Obasanjo will by June launch NIPRISAN (HEMOXIN(TM)), the locally produced drug for sickle cell disorder.

The president will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN

The drug NIPRISAN (HEMOXIN(TM), which is at present, undergoing final stage of registration with NAFDAC is a phyto-pharmaceutical drug for the treatment of patients suffering from Sickle Cell Disease (SCD). SCD is an insidious and painful genetic blood disorder often resulting in death at an early age.

Science and Technology Minister, Turner Isoun who disclosed this in Abuja noted that location of the factory in Nigeria would further crash the price of sickle cell drugs in Nigeria.

Isoun stated that Niprisan (HEMOXIN(TM)) was a drug cocktail, with phyto-pharmaceutical composition of four traditional plants extracted in a proprietary process. The licensor of the technology is the National Institute for Pharmaceutical Research and Development (NIPRD) in Abuja, Nigeria.

Nigeria is said to have the highest sickle cell disease population in the world ranging from four to six million representing roughly three to five percent of the country's population.

Isoun spoke at the inaugural meeting of the Ministers' Council for the National Biotechnology Development Agency (NABDA) where he also called on the government to involve more laboratories for the control and analysis of the bird flu menace.

On the situation of bio technology in Nigeria, he called on the stockholding agencies to ensure that Nigeria benefits from the judicious and safe use of modern biotechnology.

"Biotech is a gold mine and important to this nation. Almost every Nigerian is affected by the operations of biotech. To be able to achieve all these, we will require the concerted political will and a focused leadership drive. It is therefore the collective responsibility of all of us key stakeholders of modern biotechnology to join forces in realizing this vision.

It is my belief that this collective mission will not jeopardize our separate mandates but will promote the effective coordination of our effort towards achieving the same ultimate goal."

To achieve the nation's targets in biotech, the Director General of the National Biotechnology Development Agency (NABDA), Bamidele Solomon called for the establishment of biotechnology development fund.

The fund, he stressed, could help the nation support competent researches and be ready to tackle problems like the bird flu.

He also disclosed that Nigeria in collaboration with Trinity Biotech of the Republic of Ireland will establish a facility at SHESTCO Abuja for the production of test kits for HIV/AIDS and other diseases like HB, malaria and so on.

He added that the Federal Government has approved the sum of $28 million as counterpart commitment for the project.

He also spoke of Nigeria's collaboration with Shantha Biotechnics Limited of India for the establishment a facility for the production of Hepatitis B vaccine and other vaccines for related diseases like typhoid, polio, DTP and related ailments.

"Government approved the sum of N10 Million in the 2004 capital budget to support carrying out of a detailed feasibility study and fulfilling other MoU requirement."

[GatewayStocks]

XKEM--------By: gaycrisis
03 Mar 2006, 08:17 PM EST
Msg. 8073 of 8094

Jump to msg. #
attention: XKEM just emailed me look:

From : Steve Burg
Sent : Friday, March 3, 2006 4:31 PM
To : XXXX

Dear XXXX

Thank you for your inquiry regarding our Nicosan product in Nigeria.

We have submitted final documents to the government (NAFDAC) and are awaiting approval of our plant and the drug.

As soon as we receive that approval, we will begin selling Nicosan in Nigeria.

Steve Burg

Office: 707-425-8855

Cell: 707-326-9956

Fax: 707-421-1288

[GatewayStocks]

Major breakthrough in fight against sickle cell disease
by HERB BOYD
Special to the AmNews
Originally posted 1/4/2006

With two recent victories under its belt, there is reason for optimism at Xechem, a development stage biopharmaceutical company that has been working diligently to produce and market a drug to fight against Sickle Cell Disease (SCD).
Recently, Xechem International announced that it had acquired the exclusive, worldwide licensing rights to a new five-membered heterocyclic anti-sickling compound from Virginia Commonwealth University (VCU). "Early research has shown this anti-sickling agent to be highly effective and a relatively non-toxic treatment for Sickle Cell Disease," a press release from Xechem said. This new compound, the company stated, will further expand Xechem's portfolio of products in its fight against this disease that is so common among Africans and African Americans.
Acquiring this compound bolsters Xechem's portfolio, which already includes a license from the National Institute of Pharmaceutical Research and Development, Ministry of Health, Government of Nigeria, for the manufacture, marketing, and distribution of NICOSAN/HEMOXIN, an all natural, phyto-pharmaceutical product that has also shown enormous promise for SCD, according to Xechem.
NICOSAN/HEMOXIN has been granted an "Orphan Drug" status by both the U.S. Food and Drug Administration and the European Union's regulatory body. The company is currently preparing an Investigational New Drug (IND) application for submission to the FDA and EU agencies.
''We know of no existing non-toxic medicines available anywhere in the world for the effective treatment of Sickle Cell Disease," said Dr. Ramesh C. Pandey, Xechem's Chairman and CEO. "Between our existing product, NICOSAN™/HEMOXIN™, a non-toxic product that has shown excellent results in Phase IIA and Phase IIB clinical trials in Nigeria, and this promising new heterocyclic pharmaceutical agent being developed in collaboration with VCU, Xechem will be in a truly unique position to offer viable and efficacious treatments to patients suffering with this painful and debilitating condition."
Along with the acquisition of the VCU licensing agreement, last week Xechem announced it had settled its anti-trust lawsuit against Bristol-Myers Squibb Company for $4.2 million. The lawsuit, filed two years ago, stemmed from Xechem's allegations that Bristol Myers "had engaged in anti-competitive practices relating to Xechem's efforts to manufacture and bring to market the drug paclitaxel, a generic equivalent to Bristol's cancer drug, TAXOL ®."
The settlement, according to Dr. Pandey, will further his company's plans to launch its sickle cell drug. "The settlement with Bristol Myers could not have come at a better time for Xechem," he said.
Dr. Pandey has a distinguished career in the biomedical sciences spanning over 35 years and has served with numerous universities, government agencies and pharmaceutical companies worldwide. He came to the United States from India in 1967 with a Ph.D. in medicinal chemistry and spent three post-doctorate years at the University of Illinois-Champaign Urbana, IL with Professor Kenneth L. Rinehart, Jr.
Xechem International, Inc. is a development stage biopharmaceutical company focusing on anticancer, antiviral (including AIDS), antifungal, Sickle Cell Disease, antimalarial and antibacterial products from natural sources, including microbial and marine organisms. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its primary focus is on the development of phyto-pharmaceuticals and other proprietary technologies, including those used in the treatment of orphan diseases. Its primary attention and resources are currently being directed toward the development and commercial launch of NICOSAN™/HEMOXIN™, which has shown efficacy in the treatment of SCD.
Sickle Cell Disease is a genetic blood disorder caused by an abnormality in the hemoglobin molecule. Patients with this disease often produce stiff, abnormally shaped cells that do not flow freely through blood vessels, creating clogs in the vessels, which in turn cut off the flow of normal hemoglobin and oxygen to the body. In Nigeria alone, according to a mini-documentary produced for Xechem by DDO Group LLC Harlem Edit, more than 25% of the population are carriers of the SCD trait and over 4.5 million Nigerians (~5% of the population) are actually afflicted with the disease. Approximately 12 million people, mostly in sub-Saharan Africa, are believed to suffer from this disease worldwide.

[GatewayStocks]

I think we will see a 3-day run starting monday...Not including last friday...JMHO and GLTA

[GatewayStocks]

(SouthEnd Stock Pickers)
The SouthEnd Stock Pickers helps investors win at investing on the merits of radically original thinking and an unbeatable track record of picking stocks with huge potential. We're here for you with commonsense,the big ideas,and little inspiration to turn your portfolio into a monster performer.We've brought you GTE,GOOG,SIRI,PTSC,
CMGI,JDSU,HISC,and others you've made a killing on! If
it doesn't make commonsense,it makes no sense to us or you.At SouthEnd Stock Pickers,we're focusing solely on undervalued NASDAQ stocks that we feel will return potential profits of 500%+1 to 4 weeks .Our South End Team uses a new breakthrough method of hardcore stock picks. $$ WE ARE HERE TO MAKE YOU MONEY $$

       $$HOT PICK OF THE WEEK$$

www.xechem.com                                                         Top competitors
Xechem International,Inc,                           Bristol-Myers Squibb
Ticker Symbol= XKEM                                 www.bms.com
Market Cap=$3.32M                                      Genentech
Induustry:Biotechnology                              www.gene.com
Target Price=$0.47                                       Tapestry Pharmaceutical
Recommendation: MEGA BUY                   www.tapestrypharma.com



Many people die and suffer from a disease called Sickle Cell Anemia.People from all parts of the world carry this painful disease.Scientist and pharmaceutical industries have become forerunners in creating a cure or maintaining this painful disease.Xechem is one company who will lead the way, with many patents on hand in trying to help victims that suffer from Sickle Cell Anemia.
Many people are afflicted in Africa with Sickle Cell Anemia, particularly Nigeria.Xecchem's medical drug would assist tens of thousands of men,and woman,and children in Nigeria that are suffering.Plans are taking place to open a plant which would supplement the high demand of this drug.Bristol-Meyers Squibb,a major pharmaceutical company in America was taken to court by Xechem then settled for $4.2 million which would further launch Xechem in the direction it is headed.
The opening of the factory in Nigeria will be a significant move for Xechem.The opening will give shareholder value a shock into what will be unprecedented numbers.What would be next for the U.S market?
XECHEM: A giant in the making............

Last week SouthEndStockPickers put a Target price of $0.24
Our group put a New Target Price $0.47 Why you ask?

ALERTS WERE SET OFF with the amount accumulation of shares.We are confident that  a large Micro-Fund is absorbing all (XKEM) shares.We also believe that the company is buying back shares on the open market.

We have a very large position in (XKEM)

Accumulation...........Accumulation............ IS THE KEY WORD

[GatewayStocks]

XKEM: .0161 x .0163 Gapping...breaking through .015 resistance on the gap.

[GatewayStocks]

XKEM: +42% HOD .022

[GatewayStocks]

I would bet news in the morning; Last 4 news PR's from the XKEM were 6:30 AM EST

[GatewayStocks]

XKEM: Nigerian Govt. President Olusegun Obasanjo said they will by June launch NIPRISAN (HEMOXIN(TM)), the locally produced drug for sickle cell disorder.

This drug "IS" going to be Launched!

[brucey]

 
thanks a lot for the good infos.
Now I am out of the shadow .
I almost sold @.0105, ,i put my 1 million @.0105bid,but nobody buy,i don't know why...

[GatewayStocks]

+66%...Broke and Closed above key support of .024...HOD .026....

Look for Gapper and news in the morning!

[armor00]

Excellent info Gateway, I really appreciate your input on this stock and only bought in cause of your analysis" didnt have time to do my own research".  I pulled out at .025 for a 54% gain, I made the mistake of looking at Level II and didnt think it was going to go up higher. I will be looking to get back in if it pulls back any tomorrow.